vs
Cue Biopharma, Inc.（CUE）与万物新生（RERE）财务数据对比。点击上方公司名可切换其他公司
万物新生的季度营收约是Cue Biopharma, Inc.的2.0倍（$43.2M vs $21.9M），万物新生净利率更高（16.9% vs 7.2%，领先9.7%）
Cue Biopharma是一家临床阶段生物技术企业，专注于开发针对癌症、自身免疫性疾病和炎症疾病的新型靶向免疫疗法，其专有平台可精准调节T细胞活性，主要业务覆盖北美地区，与全球药企合作推进核心候选产品的临床试验。
万物新生集团（ATRenew Inc.）是中国领先的二手消费电子产品交易与服务平台运营商，核心业务覆盖数码产品回收、质检、翻新及售卖，运营有爱回收等知名品牌，服务覆盖个人消费者及企业客户，市场遍及国内及部分东南亚地区。
CUE vs RERE — 直观对比
营收规模更大
RERE
是对方的2.0倍
$21.9M
净利率更高
RERE
高出9.7%
7.2%
损益表 — Q4 FY2025 vs Q1 FY2023
| 指标 | | |
|---|---|---|
| 营收 | $21.9M | $43.2M |
| 净利润 | $1.6M | $7.3M |
| 毛利率 | — | — |
| 营业利润率 | 9.0% | — |
| 净利率 | 7.2% | 16.9% |
| 营收同比 | 1292.3% | — |
| 净利润同比 | 116.7% | — |
| 每股收益（稀释后） | $0.05 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CUERERE
| Q4 25 | $21.9M | — | ||
| Q3 25 | $2.1M | — | ||
| Q2 25 | $3.0M | — | ||
| Q1 25 | $421.0K | — | ||
| Q4 24 | $1.6M | — | ||
| Q3 24 | $3.3M | — | ||
| Q2 24 | $2.7M | — | ||
| Q1 24 | $1.7M | — |
净利润CUERERE
| Q4 25 | $1.6M | — | ||
| Q3 25 | $-7.4M | — | ||
| Q2 25 | $-8.5M | — | ||
| Q1 25 | $-12.3M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-8.7M | — | ||
| Q2 24 | $-10.2M | — | ||
| Q1 24 | $-12.3M | — |
营业利润率CUERERE
| Q4 25 | 9.0% | — | ||
| Q3 25 | -353.4% | — | ||
| Q2 25 | -292.3% | — | ||
| Q1 25 | -2921.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -264.2% | — | ||
| Q2 24 | -390.6% | — | ||
| Q1 24 | -737.8% | — |
净利率CUERERE
| Q4 25 | 7.2% | — | ||
| Q3 25 | -346.6% | — | ||
| Q2 25 | -287.1% | — | ||
| Q1 25 | -2911.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -259.6% | — | ||
| Q2 24 | -382.7% | — | ||
| Q1 24 | -719.1% | — |
每股收益（稀释后）CUERERE
| Q4 25 | $0.05 | — | ||
| Q3 25 | $-0.07 | — | ||
| Q2 25 | $-0.09 | — | ||
| Q1 25 | $-0.17 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.17 | — | ||
| Q2 24 | $-0.20 | — | ||
| Q1 24 | $-0.25 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $27.1M | $228.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $26.4M | $557.1M |
| 总资产 | $42.2M | $722.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CUERERE
| Q4 25 | $27.1M | — | ||
| Q3 25 | $11.7M | — | ||
| Q2 25 | $27.5M | — | ||
| Q1 25 | $13.1M | — | ||
| Q4 24 | $22.5M | — | ||
| Q3 24 | $32.4M | — | ||
| Q2 24 | $30.0M | — | ||
| Q1 24 | $41.0M | — |
总债务CUERERE
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.0M | — | ||
| Q2 24 | $2.0M | — | ||
| Q1 24 | $3.0M | — |
股东权益CUERERE
| Q4 25 | $26.4M | — | ||
| Q3 25 | $13.2M | — | ||
| Q2 25 | $18.2M | — | ||
| Q1 25 | $6.6M | — | ||
| Q4 24 | $17.5M | — | ||
| Q3 24 | $25.4M | — | ||
| Q2 24 | $21.6M | — | ||
| Q1 24 | $30.0M | — |
总资产CUERERE
| Q4 25 | $42.2M | — | ||
| Q3 25 | $31.6M | — | ||
| Q2 25 | $40.7M | — | ||
| Q1 25 | $22.3M | — | ||
| Q4 24 | $32.2M | — | ||
| Q3 24 | $44.8M | — | ||
| Q2 24 | $42.3M | — | ||
| Q1 24 | $54.0M | — |
负债/权益比CUERERE
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.09× | — | ||
| Q1 24 | 0.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.1M | — |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | -0.68× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CUERERE
| Q4 25 | $-1.1M | — | ||
| Q3 25 | $-9.0M | — | ||
| Q2 25 | $-3.4M | — | ||
| Q1 25 | $-8.2M | — | ||
| Q4 24 | $-36.3M | — | ||
| Q3 24 | $-7.5M | — | ||
| Q2 24 | $-10.0M | — | ||
| Q1 24 | $-9.8M | — |
自由现金流CUERERE
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-3.4M | — | ||
| Q1 25 | $-8.3M | — | ||
| Q4 24 | $-36.4M | — | ||
| Q3 24 | $-7.5M | — | ||
| Q2 24 | $-10.0M | — | ||
| Q1 24 | $-9.8M | — |
自由现金流率CUERERE
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -116.5% | — | ||
| Q1 25 | -1976.7% | — | ||
| Q4 24 | -2309.3% | — | ||
| Q3 24 | -225.7% | — | ||
| Q2 24 | -376.2% | — | ||
| Q1 24 | -573.0% | — |
资本支出强度CUERERE
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.9% | — | ||
| Q1 25 | 35.6% | — | ||
| Q4 24 | 4.2% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 3.2% | — |
现金转化率CUERERE
| Q4 25 | -0.68× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
RERE
暂无分部数据
